Varlilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Varlilumab
DrugBank Accession Number
DB11930
Background

Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Varlilumab
External IDs
  • CDX-1127

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Varlilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Varlilumab.
AducanumabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Varlilumab.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
0125DUV5XC
CAS number
1393344-72-3

References

General References
Not Available
PubChem Substance
347911259
Wikipedia
Varlilumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentALK-positive Diffuse Large B-cell Lymphoma / B-Cell Non-Hodgkin's Lymphoma Refractory / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Epstein-Barr Virus-Positive Mucocutaneous Ulcer / Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma / HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma, Not Otherwise Specified / High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements / Intravascular Large B-Cell Lymphoma / Large B-Cell Lymphoma With 11q Aberration / Large B-Cell Lymphoma With IRF4 Rearrangement / Plasmablastic Lymphoma / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Primary Effusion Lymphomas / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt's Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Gray Zone Lymphoma / Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Recurrent Lymphomatoid Granulomatosis / Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory Gray-Zone Lymphoma / Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Refractory Primary Mediastinal Large B-Cell Cell Lymphoma / Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentHigh Grade Glioma: Glioblastoma (GBM)1
2Active Not RecruitingTreatmentMetastatic Distal Bile Duct Adenocarcinoma / Metastatic Gallbladder Carcinoma / Metastatic Intrahepatic Cholangiocarcinoma / Recurrent Distal Bile Duct Adenocarcinoma / Recurrent Gallbladder Carcinoma / Recurrent Intrahepatic Cholangiocarcinoma / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 / Unresectable Liver Carcinoma1
2TerminatedTreatmentMelanoma1
1Active Not RecruitingTreatmentRefractory Lung Non-Small Cell Carcinoma / Stage IV Lung Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 21:01 / Updated at February 21, 2021 18:53